The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...
Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients with KIMMTRAK (tebentafusp) in 2026 through US ...
As of Wednesday, January 07, CytomX Therapeutics, Inc.’s CTMX share price has surged by 6.40%, which has investors questioning if this is right time to sell.
At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an ...
The US FDA approved 46 new drugs in 2025, despite a tumultuous year at the regulatory agency.
SOUTH SAN FRANCISCO, Calif. and MONROVIA, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel ...
Tecvayli, combined with daratumumab, shows significant efficacy in treating relapsed/refractory multiple myeloma, with improved progression-free survival and response rates. The FDA's National ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback